Comparative studies on levels of proteins, bacterial endotoxins and nucleic acids in hyaluronan preparations used to treat osteoarthritis of the knee: Could residual proteins and bacterial endotoxins relate to complications?

Japanese Pharmacology and Therapeutics

Volumn 32, Issue 10, 2004, Pages 655-662

  Ohshima, Yukio ^a   Yokota, Syunji ^a   Kasama, Kikuko ^a   Ono, Hiroshi ^a  

^a HATANO RESEARCH INSTITUTE   (Japan)

Author keywords

Bacterial endotoxin; Deoxyribonucleic acid; Hyaluronan preparation; Inflammation; Knee osteoarthritis; Protein

Indexed keywords

DNA; ENDOTOXIN; HYALURONIC ACID; NUCLEIC ACID; PROTEIN;

ARTICLE; CHICKEN; COMPARATIVE STUDY; CROSS LINKING; DNA CONTENT; DRUG CONTAMINATION; HIP OSTEOARTHRITIS; INFLAMMATION; LIGHT ABSORPTION; NUCLEIC ACID ANALYSIS; PROTEIN ANALYSIS; PROTEIN CONTENT; SPECTROPHOTOMETRY;

EID: 21044446667     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Iwata H. Pharmacologic and clinical aspects of intraarticular injection of hyaluronate. Clin Orthop Rel Res 1993; 289: 285-91.
2. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 Update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 1905-15.
3. Hinton R, Moody RL, Davis AW, Thomas SF. Osteoarthritis: diagnosis and therapeutic considerations. Am Fam Physician 2002; 65: 841-8.
4. Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Safety 2000; 23: 115-30.
5. Fukuda K, Dan H, Takayama M, Kumano F, Saitoh M, Tanaka S. Hyaluronic acid increases proteoglycan synthesis in bovine articular cartilage in the presence of Interleukin-1. J Pharmacol Exp Ther 1996; 277: 1672-5.
6. Asari A, Miyauchi S, Matsuzaka S, Ito T, Kominami E, Uchiyama Y. Molecular weight-dependent effects of hyaluronate on the arthritic synovium. Arch Histol Cytol 1998; 61: 125-35.
7. Balazs EA, Leshchiner EA. Proceedings of Nisshinbo international conference on cellulosics utilizaticn in the near future. In: Inagaki H and Philips GO editor. Cellulosics utilization: research and rewards in cellulosics. New York: Elsevier Applied Science; 1989. p. 233-42.
8. Ueno Y, Kuramoto K, Konno N, Koizumi T, Hoshiba T, Nunomura T, et al. Investigation on result of use after launch of ARTZ and ARTZ Dispo. Jpn Pharmacol Ther 1995; 23: 2151-70.
9. Hammesfahr JFR, Knopf AB, Stitik T. Safety of intra-articular hyaluronates for pain associated with osteoarthritis of the knee. Am J Orthop 2003; 32: 277-83.
10. Puttick MPE, Wade JP, Chalmers A, Connell DG, Rangno KK. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol 1995; 22: 1311-4.
11. Pullman-Mooar S, Mooar P, Sieck M, Clayburne G, Schumacher HR. Are there distinctive inflammatory flares after hylan G-F 20 intraarticular injections? J Rheumatol 2002; 29: 2611-4.
12. Ali Y, Weinstein M, Jokl P. Acute pseudogout following intra-articular injection of high molecular weight hyaluronic acid. Am J Med 1999; 107: 641-2.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
14. The Japanese Pharmacopoeia. 14th edition. 2001. p. 20-3.
15. th edition. 2002. p. 1889-93.
16. th edition. 2001. p. 140-7.
17. Beaven GH, Holiday ER, Johnson EA. The nucleic acids, vol. I. New York: Academic Press; 1955. p. 493-553.
18. Richter AW, Ryde EM, Zetterström EO. Non-immunogenicity of a purified sodium hyaluronate preparation in man. Int Archs Allergy Appl Immun 1979; 59: 45-8.
19. Chen AL, Desai P, Adler EM, Di Cesare PE. Granulomatous inflammation after hylan G-F 20 viscosupplementation of the knee. A report of six cases. J Bone Joint Surg Org 2002; 84-A: 1142-7.
20. Bucher W, Otto T. Differentiation of hyaluronate products by qualitative differences of immunogenicity in rabbit. J Rheumatol 2001; 28 (Suppl 63): 9.
21. Hamburger MI, Lakhanpal S, Mooar PA, Oster D. Intra-articular hyaluronans: A review of product-specific safety profiles. Semin Arthritis Rheum 2003; 32: 296-309.
22. Goomer RS, Leslie K, Maris T, Amiel D. Immunogenicity of hyaluronic acid products: comparison of Synvisc® and Artz® in guinea pigs. Int Cart Repr Soc (ICRS) Meeting, Toronto, June 15-8, 2002.
23. Sasaki M, Miyazaki Y, Takahashi T. Hylan G-F 20 induces delayed foreign body inflammation in guinea pigs and rabbits. Toxicol Pathol 2003; 31: 321-5.
24. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-80.
25. Dearden-Badet MT, Revillard JP. Requirement for tyrosine phosphorylation in lipopolysaccharide-induced murine B-cell proliferation. Immunology 1993; 80: 658-60.
26. Verhasselt V, Buelens C, Willems F, De Groote D, Haeffner-Cavaillon N, Goldman M. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendric cells: evidence for a soluble CD14-dependent pathway. J Immunol 1997; 158: 2919-25.
27. Terato K, Harper DS, Griffths MM, Hasty DL, Ye XJ, Cremer MA, et al. Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 1995; 22: 137-47.
28. Yoshino S, Sasatomi E, Ohsawa M. Bacterial lipopolysaccharide acts an adjuvant to induce autoimmune arthritis. Immunology 2000; 99: 607-14.
29. Otterness IG, Bliven MI, Milici A, Poole AR. Comparison of mobility changes with histological and biochemical changes during lipopolysaccharide- induced arthritis in the hamster. Am J Pathol 1994; 144: 1098-108.
30. Filion MC, Phillips NC. Pro-inflammatory activity of contaminating DNA in hyaluronic acid preparations. J Pharm Pharmacol 2001; 53: 555-61.
31. Obayashi T, Tamura H, Tanaka S, Ohki M, Takahashi S, Arai M, Masuda M, Kawai T. Removal of limulus test-interfering factors in blood samples with perchloric acid and the improvement of the specificity of the limulus test by fractionating amebocyte lysate. Prog Clin Biol Res 1987; 231: 357-69.
32. Palmer JL. Experimentally-induced synovitis as a model for acute synovitis in the horses. Equine Vet J 1994; 26: 492-5.
33. Gao B, Tsan M-F. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor a release by murine macrophages. J Biol Chem 2003; 278: 174-9.
34. Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 2002; 32: 10-37.
35. Schiavinato A, Finesso M, Cortivo R, Abatangelo G. Comparison of the effects of intra-articular injections of hyaluronan and its chemically cross-linked derivative (hylan G-F 20) in normal rabbit knee joints. Clin Exp Rheumatol 2002; 20: 445-54.
36. Mont MA, Etienne G. Sequelae of hylan G-F 20 viscosupplementation of the knee. J Bone Joint Surg Org 2003; 85-A: 967-8.
37. Kolarz G, Kotz R, Hochmayer I. Long-term benefits and repeated treatment cycles of intra-articular sodium hyaluronate (Hyalgan®) in patients with osteoarthritis of the knee. Semin Arthritis Rheum 2003; 32: 810-9.
38. Scali JJ. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee; A long term study. Eur J Rheumatol Inflamm 1995; 15: 57-62.
39. Leopold SS, Warme LCWJ, Pettis PD, Shott S. Increased frequency of acute local reaction to intra-articular hylan GF-20 (Synvisc®) in patients receiving more than one course of treatment. J Bone Joint Surg Org 2002; 84-A: 1619-23.